ライフサイエンスコーパス: dyspnea

1 pper respiratory tract infection, cough, and dyspnea.

2 tients with poorly controlled disease and/or dyspnea.

3 tted to our hospital because of wheezing and dyspnea.

4 ed urticaria and one developed urticaria and dyspnea.

5 ignificantly associated with the presence of dyspnea.

6 illing pressure in patients with unexplained dyspnea.

7 od from the rectum, progressive fatigue, and dyspnea.

8 th holding of similar duration caused severe dyspnea.

9 nts presenting to the ED with chest pain and dyspnea.

10 nts presenting to the ED with chest pain and dyspnea.

11 spital stay for patients with chest pain and dyspnea.

12 ed reflexes and sensations such as cough and dyspnea.

13 filling pressures with resultant symptoms of dyspnea.

14 patient required treatment for self-limited dyspnea.

15 rea were independently associated with worse dyspnea.

16 ith chemotherapy were fatigue, alopecia, and dyspnea.

17 ents with either condition may be limited by dyspnea.

18 emotions, to +0.96 (95% CI = 0.57-1.35) for dyspnea.

19 lc pleurodesis at relieving patient-reported dyspnea.

20 o update the 1999 ATS Consensus Statement on dyspnea.

21 uction and intermittent wheezing, cough, and dyspnea.

22 tical mechanical constraints and intolerable dyspnea.

23 associated with greater early improvement in dyspnea.

24 e syndrome including fever, hypotension, and dyspnea.

25 pressures during exercise that contribute to dyspnea.

26 year smoking history presents with cough and dyspnea.

27 ock, acutely manifested with hypotension and dyspnea.

28 % of women; P = 0.59), mainly chest pain and dyspnea.

29 lushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression (0.8% v 0.6%).

30 atios (95% confidence intervals) as follows: dyspnea-1.31 (1.10-1.56), 2.20 (1.81-2.68), and 10.73 (8

31 pain (15%), 53 of 387 with chest pain and/or dyspnea (14%), and 49 of 433 with headache (11%) returne

32 pain (25%), 72 of 387 with chest pain and/or dyspnea (19%), and 81 of 426 with headache (19%).

33 akness (26 [41%]), dysphagia (22 [35%]), and dyspnea (23 [37%]) were common.

34 rhea (54%), fatigue (50%), nausea (33%), and dyspnea (32%).

35 plus-exemestane group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue

36 ain (51%), 163 of 387 with chest pain and/or dyspnea (42%), and 103 of 433 with headache (24%).

37 The most common clinical signs were dyspnea (53.0%), diaphoresis (48.5%), and loss of consci

38 The main symptom at presentation was dyspnea (59.4%), with peripheral eosinophilia observed i

39 were anemia (10.8%), thrombocytopenia (7%), dyspnea (6.2%), and neutropenia (6.2%).

40 .5% of patients, respectively; P < .001) and dyspnea (6.5%, 4.6%, and 0.8% of patients, respectively;

41 The most common symptoms were dyspnea (67%), cough (45%), fatigue (45%), and decreased

42 Among patients with baseline dyspnea, 70% reported less dyspnea at 1 month after CTO

43 I], 1 to 12 percentage points) and help with dyspnea (78% v 70%; adjusted difference, 8 percentage po

44 t commonly reported symptoms were exertional dyspnea (78%) and fatigue (73%).

45 ); nocturnal cough (33% vs. 26%; P = 0.005); dyspnea (8% vs. 4%; P = 0.011); and use of medication (i

46 6%), a 1.6-fold increased odds of exertional dyspnea (95% CI = 1.3-1.9), a 1.5-fold increased odds of

47 a 1-week history of chest pain, progressive dyspnea, abdominal swelling, bipedal edema, and anorexia

48 The maximum dyspnea achieved during bronchial challenge correlated w

49 ociated with increase risk for self-reported dyspnea (adjusted odds ratio, 1.31; P=0.02).

50 pital because of nasal drop, itchy eyes, and dyspnea after lunch every two months for 2 years.

51 s with symptoms (often persistent) including dyspnea and a productive cough.

52 ical angina decreased, whereas patients with dyspnea and atypical angina increased.

53 Patients were adults with dyspnea and chest pain, nondiagnostic electrocardiograms

54 Changes in dyspnea and chest tightness were evaluated on a visual a

55 management would be advantageous to improve dyspnea and clinical outcomes while minimizing the risks

56 Clinical indices (lung function, dyspnea and COPD assessment test (CAT) scores) were also

57 is a clinical syndrome marked by progressive dyspnea and cough with the absence of parenchymal lung d

58 In multivariate analysis, dyspnea and disease severity significantly defined healt

59 gns and symptoms of heart failure, including dyspnea and edema due to inability of the severely disea

60 with asthma may falsely attribute exertional dyspnea and esophageal reflux to asthma, leading to exce

61 of HFpEF and one of the primary reasons for dyspnea and exercise intolerance in these patients.

62 see text]co2 in mild COPD and its impact on dyspnea and exercise intolerance.

63 ion and mastery domains) and physical score (dyspnea and fatigue domains) (P < 0.05).

64 complaining of unspecific symptoms, such as dyspnea and fatigue.

65 h colorectal cancer (CRC) often present with dyspnea and fatigue.

66 Furthermore, since he developed progressive dyspnea and hypoxemia, he was admitted to our hospital.

67 Noninvasive ventilation reduces dyspnea and improves exercise performance, but current s

68 alve implantation and usually presented with dyspnea and increased gradients.

69 No change in dyspnea and minor changes in health status occurred in t

70 Furthermore, she complains of dyspnea and nausea and vomits approximately twice per da

71 ing surgical repair of the mitral valve, the dyspnea and palpitations resolved.

72 e who presented with progressively worsening dyspnea and palpitations.

73 We examined the prevalence of dyspnea and predictors of its improvement among patients

74 malignant pleural effusions have significant dyspnea and shortened life expectancy.

75 Upper airway involvement can also lead to dyspnea and suffocation.

76 Moreover, maximum dyspnea and the Borg-oxygen uptake (V'O2) slope were sig

77 1.5%), fatigue (51.5%), pyrexia (42.4%), and dyspnea and thrombocytopenia (each 39.4%) were the most

78 Dyspnea and ventricular pauses were more common during t

79 t, a 35-year-old woman, was homebound due to dyspnea and worsening cyanosis.

80 t Pain), patients with stable chest pain (or dyspnea) and intermediate pretest probability for obstru

81 rrhea, loss of sense of smell, wheezing, and dyspnea) and on quality-of-life scores, irrespective of

82 spiratory tract (cough, wheeze, stridor, and dyspnea), and/or the gastrointestinal tract (persistent

83 s, all-cause mortality, quality of life, and dyspnea); and treatment harms.

84 3-year mortality and the predictors of age, dyspnea, and airflow obstruction were available.

85 italization within the previous 36 h, active dyspnea, and any of the following: 1) estimated glomerul

86 In patients hospitalized with AHF, dyspnea, and congestion, the addition of tolvaptan to a

87 episodic or persistent symptoms of wheezing, dyspnea, and cough.

88 te walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pul

89 h left ventricular ejection fraction </=40%, dyspnea, and elevated plasma concentrations of natriuret

90 higher Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) index (0.31 [0.19

91 nd the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index.

92 ), and body mass index, airflow obstruction, dyspnea, and exercise capacity index (adjusted beta = 0.

93 BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index, -1.8 points (all

94 measures: body mass index, lung obstruction, dyspnea, and exercise capacity.

95 cores, Body-mass index, airflow Obstruction, Dyspnea, and Exercise index, or Global Initiative for Ch

96 lier dynamic mechanical constraints, greater dyspnea, and exercise intolerance in mild COPD.

97 o2 and its impact on operating lung volumes, dyspnea, and exercise tolerance in these patients.

98 ients with abdominal pain, chest pain and/or dyspnea, and headache; P < .0001); median post-CT confid

99 hese 5 patients had a history of progressive dyspnea, and the anomalous cord, which was intact at ope

100 es after ingestion, he experienced coughing, dyspnea, and wheezing and had to be treated by anti-hist

101 ntially compatible with AF, such as fatigue, dyspnea, and/or palpitations.

102 ar outflow tract obstruction and symptoms of dyspnea, angina, and syncope.

103 tom domains (fatigue, nausea/vomiting, pain, dyspnea, anorexia, and constipation).

104 Attention to symptoms of weight gain and dyspnea are central tenets of patient education in heart

105 Palpitations and dyspnea are fundamental to the human experience of panic

106 HF symptoms, especially exertional dyspnea, are common in ARVC/D; yet, classic left-sided s

107 Patients with dyspnea as a major symptom were categorized as having HF

108 ssification schema based on patient-reported dyspnea assessed both pre- and post-ultrafiltration, in

109 Dyspnea (assessed using a 7-point Likert scale) and hemo

110 ints included the clinical congestion score, dyspnea assessment, net urine output, and net weight cha

111 nts with baseline dyspnea, 70% reported less dyspnea at 1 month after CTO PCI.

112 uration were associated with more persistent dyspnea at 24 h (>1 to 12 months, odds ratio [OR]: 1.20;

113 rollment predicted higher risk of persistent dyspnea at 6 hours (per 10 patient increase: odds ratio

114 dpoint was a 7-point change in self-assessed dyspnea at 8 and 16 h, using a novel standardized approa

115 A total of 800 (81%) reported some dyspnea at baseline with a mean (+/-SD) Rose Dyspnea Sca

116 failure, systolic blood pressure >125 mm Hg, dyspnea at rest or with mild exertion, intravenous diure

117 Congestive heart failure, paraplegia, dyspnea at rest, and reoperation are associated with the

118 tive heart failure, paraplegia, reoperation, dyspnea at rest, nongastric band surgery, age >/=60 year

119 all participants reporting palpitations and dyspnea at the 2 mug dose.

120 dysgeusia (both incidence and severity) and dyspnea (both incidence and severity) in the second pati

121 ced CT group], two patients with progressive dyspnea [both in the contrast-enhanced CT group], and on

122 ly proven HFpEF (n=50) and participants with dyspnea but no identifiable cardiac pathology (n=24).

123 equently present with exertional fatigue and dyspnea, but the hemodynamic basis for exercise limitati

124 Exertional dyspnea, chest pain, palpitations, and ankle swelling we

125 lated missing data by omitting the predictor dyspnea cohort-wide, and we present 6 methods for handli

126 The geographical, anthropometrics, FEV1, dyspnea, comorbidities, and health status scores were me

127 nce and relief of common symptoms (ie, pain, dyspnea), concordance with patients' wishes for EOL care

128 ential diagnosis of patients presenting with dyspnea, congestion, and a normal ejection fraction.

129 ted high rates of severe symptoms, including dyspnea, constipation, low appetite, fatigue, depression

130 se HRQoL with respect to cognitive function, dyspnea, constipation, thirst, leg swelling, numbness, d

131 orted treatment-emergent adverse events were dyspnea, cough, and increased sputum.

132 apnea evoked by stimulation and expressed no dyspnea, despite being awake and vigilant.

133 Dyspnea, difficulty in walking or climbing, fatigue/incr

134 Exertional dyspnea disproportionate to pulmonary function tests, lo

135 elor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were

136 We sought to evaluate the perception of dyspnea during bronchial challenge and exercise testing

137 ction are strongly related to an increase in dyspnea during bronchial provocation with methacholine.

138 The increase in dyspnea during the methacholine provocation was strongly

139 In patients with unexplained dyspnea, E/e' ratio neither accurately estimates PAWP no

140 toms (eg, odynophagia, dysphagia, dysphonia, dyspnea, earache, nasal obstruction) occurred in 48 (98%

141 tolvaptan to a background diuretic improved dyspnea early in patients selected for an enhanced vasop

142 ression from PDD to symptomatic HF including dyspnea, edema, and fatigue.

143 ically meaningful benefits in lung function, dyspnea, exercise tolerance, and quality of life, with a

144 and fatigue; grade 3 or higher AEs included dyspnea, fatigue, and SSTD.

145 arging cervical lymphadenopathy, progressive dyspnea, fatigue, night sweats, and an unintentional wei

146 higher than 30 mm Hg may be associated with dyspnea-fatigue symptomatology.

147 ly respiratory (five patients with new-onset dyspnea [four in contrast-enhanced CT group and one in u

148 try included normal adjusted mean values for dyspnea grade (0.8), St. George's Respiratory Questionna

149 R, 4.80; 95% CI, 1.68-13.69; P = 0.003), MRC dyspnea grade (OR, 2.57; 95% CI, 1.44-4.59; P = 0.001),

150 ; P = 0.015), Medical Research Council (MRC) dyspnea grade (OR, 4.57; 95% CI, 2.62-7.95; P < 0.001),

151 ype III (PIIINP) was significantly higher in dyspnea group than in controls (p = 0.01).

152 d biomarkers were assessed in control group, dyspnea group, and HF group.

153 A 56-year-old man who developed hypotension, dyspnea, hypoxia, and pulseless electrical activity 10 d

154 Notably, lung function and dyspnea improved to the baseline level by day 4 as well,

155 y noncardiac causes of dyspnea reported less dyspnea improvement after CTO PCI.

156 , and lung disease were associated with less dyspnea improvement after PCI.

157 -h PEFR change related to moderate or marked dyspnea improvement by DI (adjusted odds ratio: 1.04 for

158 and patients experiencing moderate or marked dyspnea improvement on day 1 were classified as early re

159 ul CTO PCI was associated with more frequent dyspnea improvement than failure, even after adjustment

160 Dyspnea improvement was defined as a >/=1 point decrease

161 Predictors of dyspnea improvement were examined with a modified Poisso

162 nous OM did not meet the primary endpoint of dyspnea improvement, but it was generally well tolerated

163 emodynamic measurements during treatment and dyspnea improvement.

164 ding lung function (100 ml for trough FEV1), dyspnea (improvement of >/= 1 unit in the Transition Dys

165 Based on studies on dyspnea in cardiopulmonary diseases, including asthma an

166 ine, to induce sensations of palpitation and dyspnea in healthy individuals (n=23) during arterial sp

167 ced coronary blood flow and the sensation of dyspnea in human subjects.

168 The mechanisms underlying dyspnea in interstitial lung disease (ILD) and chronic o

169 Malignant pleural effusion causes disabling dyspnea in patients with a short life expectancy.

170 olic ejection time, and it may have improved dyspnea in the high-dose group.

171 adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-

172 atching (increased dead space) and resultant dyspnea, independent of markers of cardiac function.

173 t (SLS-I and II) using 2 anchors: Transition Dyspnea Index (>/=change of 1.5 units for improvement an

174 ose FEV1, 2-h post-dose FEV1, and Transition Dyspnea Index (TDI) focal score, all measured at week 26

175 st total score of 10 or more, and a Baseline Dyspnea Index focal score of 10 or less.

176 ory Questionnaire total score and transition dyspnea index total score and reduction in daily rescue

177 (improvement of >/= 1 unit in the Transition Dyspnea Index total score or 5 units in the University o

178 ratory Questionnaire total score, transition dyspnea index total score, and reduction in rescue medic

179 Medical Research Council scale and baseline dyspnea index), quality of life (QoL), mood disorders, e

180 th was associated with a greater increase in dyspnea intensity (P = 0.0005).

181 The relationship between dyspnea intensity and EMGdi/EMGdi,max during exercise wa

182 id not influence the key association between dyspnea intensity and inspiratory neural drive to the di

183 Standardized dyspnea intensity ratings were also higher (P<0.05) in p

184 Dyspnea is a common angina equivalent that adversely aff

185 Dyspnea is a common symptom among patients undergoing CT

186 Dyspnea is a common, distressing symptom of cardiopulmon

187 A clinically significant improvement in dyspnea is associated with a reduction in both PCWP and

188 uation should be suggested when dysphonia or dyspnea is observed at the acute stage of SJS/TEN.

189 Dyspnea is the most common symptom among hospitalized pa

190 PE, 2-pillow orthopnea, paroxysmal nocturnal dyspnea, left and right ventricular structure and functi

191 ncil [mMRC] scale 0 to 4; 4 represents worse dyspnea; MCID, 0.7 units), baseline 6-minute walk distan

192 Secondary outcomes were baseline measures of dyspnea (modified Medical Research Council [mMRC] scale

193 , 44.3 pack-years), we evaluated spirometry, dyspnea (modified Medical Research Council grade, >/=2),

194 pic diseases), symptoms (chronic bronchitis, dyspnea-modified Medical Research Council scale and base

195 llow-up examination of survivors, persistent dyspnea (mostly mild) or functional limitation was repor

196 r spirometry (n = 697), cough (n = 722), and dyspnea (n = 1,050).

197 common clinical presentation was exertional dyspnea (n=17; 65%), whereas 8 (31%) patients had no wor

198 ubjects (age 67 +/- 9 years) with exertional dyspnea (New York Heart Association functional class II

199 with stage C heart failure (HF) (exertional dyspnea, New York Heart Association functional class II

200 Subjects were adults with chest pain and dyspnea, nondiagnostic ECGs, and no obvious diagnosis.

201 y more patient complaints of acute transient dyspnea occurred after gadoxetate disodium administratio

202 nt were low in both groups, though transient dyspnea occurred significantly more frequently with cang

203 ion of flatfish and yellowtail, pruritus and dyspnea occurred.

204 flatfish, sea bream and mackerel, wheals and dyspnea occurred.

205 erval [CI], 1.30-2.12), paroxysmal nocturnal dyspnea (odds ratio 1.95; 95% CI, 1.55-2.44), and abnorm

206 he developed a nonproductive cough and mild dyspnea on exertion (Modified Medical Research Council d

207 sweats, weight loss, shortness of breath or dyspnea on exertion, or cough.

208 sented with a persistent cough and worsening dyspnea on exertion.

209 2.7% were women, and 87.7% had chest pain or dyspnea on exertion.

210 Dyspnea or dysphonia were significantly associated with

211 Presenting signs and symptoms included dyspnea or heart failure in 67% and atrial arrhythmias i

212 Although wheezes, dyspnea or loss of consciousness are known to occur with

213 er cough, sputum, fever/chills/night sweats, dyspnea or pleuritic chest pain) or with Pneumonia-in-Pl

214 928 of 2395 (38.8%) with available data had dyspnea or respiratory distress, and hospitalizations oc

215 es, and it did not appear to reduce residual dyspnea or RV dysfunction in these patients.

216 or CT with abdominal pain, chest pain and/or dyspnea, or headache were identified.

217 Shortness of breath, dyspnea, or respiratory distress or failure at hospital

218 On exercise dyspnea patients had lower early diastolic (E') and syst

219 Control and dyspnea patients had lower levels of cardiotrophin-1, cy

220 tion of fever, higher morbidity of tachypnea/dyspnea, pleural effusion, diarrhea, hepatosplenomegaly,

221 most common treatment-emergent SAEs included dyspnea, pneumonia, febrile neutropenia, dehydration, an

222 No independent association was found with dyspnea, QoL, exacerbations, and mortality.

223 Disease severity (dyspnea, QoL, exacerbations, comorbidities) and prognosi

224 ore predictive of measures of lung function, dyspnea, quality of life, and health care use.

225 Isotime dyspnea reduction correlated with isotime EMG reduction

226 At day 3, dyspnea reduction was greater with tolvaptan (p = 0.01).

227 difference in the primary endpoint of day 1 dyspnea reduction, despite significantly greater weight

228 ompanied by respiratory muscle unloading and dyspnea reductions in patients with severe hypoxemic COP

229 Hg) and the percentage of patients achieving dyspnea relief (17.7%, 24.6%, 32.2%, 36.2%, 37.8%, 47.4%

230 , OM did not improve the primary endpoint of dyspnea relief (3 OM dose groups and pooled placebo: pla

231 e temporal relationship between diuresis and dyspnea relief and a possible clinical role for tolvapta

232 independently associated with greater early dyspnea relief and improved post-discharge survival comp

233 However, the association between short-term dyspnea relief and postdischarge clinical outcomes and h

234 e-specified analyses, OM resulted in greater dyspnea relief at 48 h (placebo, 37% vs. OM, 51%; p = 0.

235 Dyspnea relief by Likert scale was similar between group

236 Dyspnea relief constitutes a major treatment goal and a

237 In patients with acute heart failure (AHF), dyspnea relief is the most immediate goal.

238 Although dyspnea relief remains a goal of therapy for hospitalize

239 Dyspnea relief was defined as moderate or marked improve

240 by discharge, whereas patient-reported early dyspnea relief was reported by 610 patients (40%).

241 PCWP quartile, the adjusted odds ratios for dyspnea relief were 0.92 (95% confidence interval [CI],

242 ssure quartile, the adjusted odds ratios for dyspnea relief were 2.0 (95% CI, 1.41-2.82), 2.23 (95% C

243 ction at 72 hours are poorly correlated with dyspnea relief.

244 pressure were independently associated with dyspnea relief.

245 with other potentially noncardiac causes of dyspnea reported less dyspnea improvement after CTO PCI.

246 ergometer exercise and associated effects on dyspnea, respiratory muscle activation, and pulmonary ga

247 6MWD), the Modified Medical Research Council Dyspnea Scale (mMRC), the COPD Assessment Test (CAT), St

248 82%) were assessed for dyspnea with the Rose Dyspnea Scale at baseline and 1 month after CTO PCI.

249 was defined as a >/=1 point decrease in Rose Dyspnea Scale from baseline to 1 month.

250 dyspnea at baseline with a mean (+/-SD) Rose Dyspnea Scale of 2.8+/-1.2.

251 exertion (Modified Medical Research Council dyspnea scale score of 2 [ie, he had to stop for breath

252 Rose Dyspnea Scale scores range from 0 to 4 with higher score

253 n, body mass index, Medical Research Council dyspnea scale, disease severity, and demographic data we

254 ime to clinical worsening, score on the Borg dyspnea scale, quality-of-life variables, and safety.

255 e 12-Item Short Form Health Survey, the Rose Dyspnea Scale, the Patient Health Questionnaire-8, and t

256 me to clinical worsening (P=0.005), and Borg dyspnea score (P=0.002).

257 correlated with the Medical Research Council dyspnea score (r = 0.34; P < 0.0001), FEV1% predicted (r

258 ospital admissions, Medical Research Council dyspnea score greater than or equal to 4, FEV1 < 30% pre

259 .5 points; modified Medical Research Council dyspnea score, -0.6 points; and BODE (body mass index, a

260 onal class, time to clinical worsening, Borg dyspnea score, quality-of-life variables, and safety.

261 s no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any ca

262 ry and impulse oscillometry, as well as Borg dyspnea scores at baseline and during a methacholine pro

263 Dyspnea scores during adenosine bronchial challenge and

264 echanical inspiratory constraints and higher dyspnea scores for a given work rate leading to poorer e

265 g-swallowing synchronization, and Borg Scale dyspnea scores improved significantly with noninvasive m

266 as associated with a higher increase in Borg dyspnea scores in subjects with asymptomatic BHR, but no

267 EMG, Spo(2), transcutaneous Pco(2), and Borg dyspnea scores.

268 associated with improved patient comfort and dyspnea scores.

269 teroception, including a complete absence of dyspnea sensation.

270 pirometry and multiple phenotypes, including dyspnea severity (Modified Medical Research Council grad

271 c, reported a complete lack of awareness for dyspnea, suggestive of impaired respiratory interoceptio

272 e disodium can result in acute self-limiting dyspnea that can have a deleterious effect on arterial p

273 e nonmajor, and 86% of adverse events due to dyspnea that led to discontinuation of treatment with ti

274 In patients symptomatic for dyspnea, the occurrence of DeltaVO2/DeltaWR flattening r

275 ression defined by 48-week worsening of FVC, dyspnea (University of California, San Diego Shortness o

276 examine whether triggering palpitations and dyspnea via stimulation of non-chemosensory interoceptiv

277 vel-and relief of symptoms as defined by the dyspnea visual analog scale area under the curve.

278 tongue swellings (8.7%) were associated with dyspnea, voice changes, and imminent asphyxiation.

279 Apparent subsequent differences in dyspnea warrant further exploration of the temporal rela

280 The mean prevalence of NSAID-induced dyspnea was 1.9% and was highest in the three Polish cen

281 Control Test (ACT) score <20 (n = 287), and dyspnea was defined as a modified Medical Research Counc

282 Dyspnea was limited to grade 1/2 in 10 patients.

283 Patient-reported dyspnea was measured using a 7-point Likert scale, and p

284 Physician-assessed and patient-reported dyspnea was not independently associated with HRQOL, all

285 tal physician-assessed, and patient-reported dyspnea was not independently associated with postdischa

286 Physician-assessed dyspnea was rated as frequent or continuous in 1399 pati

287 Perception of dyspnea was rated with the Borg score during the provoca

288 Physician-assessed dyspnea was recorded on a daily basis from baseline unti

289 Spirometric findings, health status, and dyspnea were also monitored.

290 Physical functioning, constipation, and dyspnea were independent significant prognostic factors

291 Patients with dyspnea were more likely to be female, obese, smokers, a

292 t, minor allergic symptoms of urticarial and dyspnea were observed on two occasions, but they disappe

293 a, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased.

294 o leads to background symptomatology such as dyspnea, which can mask the clinical diagnosis of cardia

295 normal breathing-swallowing interactions and dyspnea, which improved with noninvasive mechanical vent

296 s attributable to an increased perception of dyspnea, which, during exercise, is mainly associated wi

297 ardiography in 118 patients with unexplained dyspnea who underwent right heart catheterization.

298 om 0 to 4 with higher scores indicating more dyspnea with common activities.

299 consists of unexplained fever, weight gain, dyspnea with pulmonary infiltrates, pleuropericardial ef

300 CI (procedure success 82%) were assessed for dyspnea with the Rose Dyspnea Scale at baseline and 1 mo